Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 11/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.74 |
| ▸ | HDAC4 | P56524 | 12/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.74 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.74 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.74 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.74 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.68 |
| ▸ | MEF2D | Q14814 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392550 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC4HDAC8 | |
| SCHEMBL29354058 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC4HDAC8 | |
| SCHEMBL675747 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC4HDAC8 | |
| SCHEMBL1236293 | 0.89 | HDAC3 (0.80) | HDAC1HDAC3HDAC2HDAC4HDAC8 | |
| SCHEMBL11974531 | 0.89 | HDAC3 (0.80) | HDAC1HDAC3HDAC2HDAC4HDAC8 | |
| SCHEMBL1236290 | 0.89 | HDAC3 (0.80) | HDAC1HDAC3HDAC2HDAC4HDAC8 | |
| SCHEMBL392628 | 0.87 | HDAC3 (0.77) | HDAC1HDAC3HDAC2HDAC4HDAC8 | |
| SCHEMBL11984101 | 0.86 | HDAC1 (0.76) | HDAC1HDAC3HDAC2HDAC4HDAC8 | |
| SCHEMBL25049810 | 0.85 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC4HDAC8 | |
| SCHEMBL11886047 | 0.85 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC4HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000031-B2 | Thioxanthone-based autophagy inhibitor therapies to treat cancer | SPECTRUM PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | claimed |
| US-8524762-B2 | Thioxanthone-based autophagy inhibitor therapies to treat cancer | SPECTRUM PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | claimed |
| EP-2544673-A1 | THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER | Spectrum Pharmaceuticals, Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| US-20110275696-A1 | Thioxanthone-Based Autophagy Inhibitor Therapies to Treat Cancer | SPECTRUM PHARMACEUTICALS, INC. | 2011-11-10 | — | — | US | claimed |
| WO-2011112623-A1 | THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER | SPECTRUM PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | claimed |
| EP-2135620-A1 | OCULAR HYPOTENSIVE AGENT COMPRISING COMPOUND CAPABLE OF INHIBITING HISTONE DEACETYLASE AS ACTIVE INGREDIENT | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-23 | — | — | EP | claimed |
| WO-2008090534-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF EXCESSIVE WEIGHT GAIN, REDUCTION OF INAPPROPRIATE EATING BEHAVIOURS AND INHIBITION OF BINGE EATING FOR THE TREATMENT OF OBESITY | BERAND LIMITED (IE) | 2008-07-31 | — | — | WO | claimed |
| WO-2007049262-A1 | Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders | BERAND LIMITED (IE) | 2007-05-03 | — | — | WO | claimed |
| US-20040157930-A1 | Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs | ITALFARMACO S.P.A. (IT) | 2004-08-12 | — | — | US | claimed |
| US-11357748-B2 | Methods for treating mendelian disorders of the epigenetic machinery | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-06-14 | — | — | US | disclosed |
| US-11332716-B2 | Methods and compositions for producing pancreatic beta cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3024926-B1 | GENERATING DEFINITIVE ENDODERM AND PANCREATIC PROGENITOR CELLS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10568854-B2 | Compositions and methods for treating kabuki syndrome and related disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| EP-3039126-B1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20070254835-A1 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISORDERS | SUPERGEN INC. | 2007-11-01 | — | — | US | disclosed |
| US-7276228-B2 | Methods for treating hematological disorders through inhibition of DNA methylation and histone deacetylase | SUPERGEN, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| WO-2007031853-A2 | THERAPEUTIC COMBINATION OF HAMLET AND A HDAC INHIBITOR TO TREAT CANCER | NYA HAMLET PHARMA AB (DK) | 2007-03-22 | — | — | WO | disclosed |
| US-20040157930-A1 | Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs | ITALFARMACO S.P.A. (IT) | 2004-08-12 | — | — | US | disclosed |
| WO-2003032921-A2 | TREATMENT OF NEURODEGENERATIVE DISEASES AND CANCER OF THE BRAIN | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157930-A1 | Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs | HDAC1, HDAC2, HDAC5 | HDAC1 1/4885HDAC3 6/4885HDAC2 2/4885 |
| US-11332716-B2 | Methods and compositions for producing pancreatic beta cells | IAPP, ALPG, AMY2A | HDAC1 4012/4885HDAC3 3990/4885HDAC2 4253/4885 |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | HDAC1, HDAC9, HDAC5 | HDAC1 1/4885HDAC3 9/4885HDAC2 8/4885 |
| US-20110275696-A1 | Thioxanthone-Based Autophagy Inhibitor Therapies to Treat Cancer | ATG7, BECN1, SQSTM1 | HDAC1 464/4885HDAC3 418/4885HDAC2 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.